Sorafenib has been the standard of care for unresectable HCC since its approval in 2007.10 In recent years, approvals of the new TKIs (lenvatinib as the first line and regorafenib and cabozantinib as the second line) and immune checkpoint blocking antibodies (nivolumab and pembrolizumab, both blocking PD-1) have energized the field to seek novel targets and drug combinations for HCC treatment. Here, PDCD1 is linked to hepatocellular carcinoma.